序号 |
标题 |
次数 |
作者 |
发布时间 |
82891 |
DOTA−Lysine−Biotin, DOTA -赖氨酸-生物素 |
114 |
wyh |
2024-12-03 |
82892 |
DOTA-GA,螯合剂DOTA肽缀合物 |
137 |
wyh |
2024-12-03 |
82893 |
DOTA共轭二膦酸盐,DOTA-HBP |
130 |
wyh |
2024-12-03 |
82894 |
DOTA-神经介素n ,DOTA-Neuromedin N |
112 |
wyh |
2024-12-03 |
82895 |
tris-烯丙基-DOTA , tris-allyl-DOTA |
93 |
wyh |
2024-12-03 |
82896 |
6-(苄氧羰基)氨基-3-(甲硫基)-1,2,4-四嗪;6-(benzyloxycarbonyl)amino-3-(methylthio)-1,2,4,5-tetrazine |
116 |
WYQ |
2024-12-03 |
82897 |
6-(乙酰氨基)-3-(甲硫基)-1,2,4-四嗪;6-(acetylamino)-3-(methylthio)-1,2,4,5-tetrazine |
135 |
WYQ |
2024-12-03 |
82898 |
cFLFLFK-PEG-DOTA ;细胞特异性肽-聚乙二醇-DOTA |
84 |
wyh |
2024-12-03 |
82899 |
6-[(叔丁氧基羰基)氨基]-3-(甲硫基)-1,2,4-四嗪;6-[(tert-butyloxycarbonyl)amino]-3-(methylthio)-1,2,4,5-tetrazine |
116 |
WYQ |
2024-12-03 |
82900 |
MMA-DOTA-Cys 61 ,DOTA-马来酰亚胺-半胱氨酸 |
142 |
wyh |
2024-12-03 |
82901 |
DOTA-BR96 ,DOTA标记BR96单克隆抗体 |
116 |
wyh |
2024-12-03 |
82902 |
DOTA-ggNle-cycmsh(hex),内酰胺桥环化肽偶联DOTA |
105 |
wyh |
2024-12-03 |
82903 |
DOTA-sCCK8[Phe2(p-CH2SO3H) ,大环DOTA偶联多肽 |
108 |
wyh |
2024-12-03 |
82904 |
3,6-双(1H-1,2,3,4-四唑-5-基氨基)-1,2,4,5-四嗪(BTATz);3,6-bis(1H-1,2,3,4-tetrazol-5-yl-amino)- 1,2,4,5-tetrazine |
120 |
WYQ |
2024-12-03 |
82905 |
3,3'-偶氮二(6-氨基-1,2,4,5-四嗪)(DAAT);3,3'-azobis(6-amino-1,2,4,5-tetrazine) |
225 |
WYQ |
2024-12-03 |
82906 |
c(DOTA-RGDf),大环螯合剂DOTA环化RGD肽序列 |
116 |
wyh |
2024-12-03 |
82907 |
3,6-双(吡啶-3-基)-1,2,4,5-四嗪(3,3'-吡喃);3,6-bis(pyridin-3-yl)-1,2,4,5-tetrazine (3,3'-pytz) |
120 |
WYQ |
2024-12-03 |
82908 |
3,6-双(2-甲氧基苯基)-1,2-二氢-1,2,4,5-四嗪(2-MDHT);3,6-bis(2-methoxyphenyl)-1,2-dihydro-1,2,4,5-tetrazine |
132 |
WYQ |
2024-12-03 |
82909 |
3,6-二甲基-1,2,4,5-四嗪;3,6-Dimethyl-1,2,4,5-tetrazine |
131 |
WYQ |
2024-12-03 |
82910 |
3,3'-偶氮(6-氨基-1,2,4,5-四嗪);3,3'-Azobis(6-amino-1,2,4,5-tetrazine)(DAAT) |
161 |
WYQ |
2024-12-03 |
82911 |
3,6-d二肼基-1,2,4,5-四嗪(DHT) |
119 |
WYQ |
2024-12-03 |
82912 |
DOTA-D-phe1-Tyr3-奥曲肽 ,Ga-68-DOTA-TATE |
99 |
wyh |
2024-12-03 |
82913 |
DOTA-cCCK,DOTA偶联胆囊收缩素(CCK)受体 |
126 |
wyh |
2024-12-03 |
82914 |
3,6-d氨基-1,2,4,5-四嗪(DATZ) |
117 |
WYQ |
2024-12-03 |
82915 |
3-d氨基-6-(3,5-二甲基乙基吡唑-1-基)-1,2,4,5-四嗪(ADMPT) |
140 |
WYQ |
2024-12-03 |
82916 |
[DOTA]LTT-SS28 ,生长抑素模拟物 |
152 |
wyh |
2024-12-03 |
82917 |
DOTA-minigastrin (CP04) , DOTA-小胃泌素(CP04) |
154 |
wyh |
2024-12-03 |
82918 |
DOTA-rhuEpo ; DOTA-酰肼偶联rhuEpo |
95 |
wyh |
2024-12-03 |
82919 |
1,2,4,5-四嗪 , 化学式:C2H2N4 |
179 |
WYQ |
2024-12-03 |
82920 |
DOTA-Benerotide ;靶向生长抑素受体 |
88 |
wyh |
2024-12-03 |
82921 |
1,2,4,5-Tetrazines by Palladium Catalysis(钯催化1,2,4,5-四嗪的合成) |
106 |
WYQ |
2024-12-03 |
82922 |
5-苯基-1,2,4-三嗪-3-胺为例,为C9H8N4 |
104 |
WYQ |
2024-12-03 |
82923 |
DOTA-PEG-LA-AuNP,DOTA-PEG-硫辛酸修饰纳米金纳米粒子 |
122 |
wyh |
2024-12-03 |
82924 |
3,6-二(吡啶-2-基)-1,2,4,5-四嗪(pytz) |
154 |
WYQ |
2024-12-03 |
82925 |
HYNIC-PEG11-Tz;联肼尼克酰胺-十一聚乙二醇-四嗪;HYNIC-PEG11-Tetrazine |
103 |
WYQ |
2024-12-03 |
82926 |
DOTA-NT肽偶联金纳米粒子 ,DOTA-NT-AuNPs |
107 |
wyh |
2024-12-03 |
82927 |
[Zr-89]Zr-DFO-PEG5-Tz;[Zr-89]Zr-DFO-PEG5-Tetrazine |
118 |
WYQ |
2024-12-03 |
82928 |
MeTz-NOTA-RGD;甲基四嗪-大环配体-多肽 |
149 |
WYQ |
2024-12-03 |
82929 |
DOTA-Tyr(3)-奥曲肽, DOTA-Tyr(3)-Octreotide |
88 |
wyh |
2024-12-03 |
82930 |
AgNPs–pytz(3,6-二(吡啶-2-基)-1,2,4,5-四嗪包覆的银纳米粒子) |
106 |
WYQ |
2024-12-03 |
82931 |
3,6-di(pyridin-2-yl)-1,2,4,5-s-tetrazine (pytz,3,6-二(吡啶-2-基)-1,4-二氢-1,2,4,5-四嗪) |
133 |
WYQ |
2024-12-03 |
82932 |
DOTA-叶酸偶联物,DOTA-Folate |
135 |
wyh |
2024-12-03 |
82933 |
CQDs-DOTA-Yb,镱-DOTA螯合物功能化碳量子点 |
111 |
wyh |
2024-12-03 |
82934 |
3,6-dihydrazino-s-tetrazine (DHT,3,6-二肼基-s-四嗪) |
122 |
WYQ |
2024-12-03 |
82935 |
BCN-PEG-PAMAM ,环丙烷环辛炔-聚乙二醇-聚酰胺 |
112 |
zyl |
2024-12-03 |